Supernus Pharmaceuticals Inc/ US8684591089 /
03/09/2024 22:00:00 | Chg. -0.4500 | Volume | Bid00:36:25 | Ask00:36:25 | High | Low |
---|---|---|---|---|---|---|
34.7100USD | -1.28% | 380,700 Turnover: 8.46 mill. |
33.2300Bid Size: 100 | 35.7400Ask Size: 100 | 34.9300 | 34.3900 |
GlobeNewswire
28/08
Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
GlobeNewswire
19/08
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
GlobeNewswire
23/07
Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call ...
GlobeNewswire
30/05
Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
GlobeNewswire
23/05
Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epile...
GlobeNewswire
21/05
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmac...
GlobeNewswire
12/05
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmac...
GlobeNewswire
09/05
Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa St...
GlobeNewswire
02/05
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmac...
GlobeNewswire
24/04
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call o...
GlobeNewswire
24/04
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmac...